PTEN gene expression in Patients with Ankylosing spondylitis



Background: Ankylosing spondylitis (AS), the most common form of spondyloarthropathy, is a chronic, progressive multi-system inflammatory disorder characteristically affecting the sacroiliac joints and axial skeleton. The protein encoded by the PTEN gene which has a phosphatase activity, plays a key role in many of the signaling pathways, such as cell cycle regulation, cell migration, apoptosis and angiogenesis, therefore, it can be one of the candidate genes associated with autoimmune diseases, such as ankylosing spondylitis. The aim of this study was to evaluate the expression of PTEN gene in patients with AS and compare to healthy individuals in Iranian population. Methods: The present case-control study was consisted of 50 patients with AS and 50 healthy controls recruited from those referred to Shohada Hospital, Tajrish,Tehran in 1394. The RNA was extracted from peripheral blood leukocytes and subsequently the PTEN gene expression was investigated in both groups using real-time PCR. Results: The results showed that PTEN expression was significantly decreased in patients compared to control group (P=0.02). Conclusion: The PTEN gene expression can be considered as parameter for screening and early diagnosis of individuals susceptible to this disease.


1.Wanders A, Heijde Dvd, Landewé R, Béhier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis & Rheumatism 2005; 52(6): 1756-65. 2.Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012; 71(10): 1616-22. 3. Prajzlerová K, Grobelná K, Hušáková M, Jüngel A, Gay S, Vencovský J, et al., Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis. PLoS One 2017; 12(9): e0185323. 4. Danve A, O'Dell J.The ongoing quest for biomarkers in Ankylosing Spondylitis. Int J Rheum Dis 2015;18(8):826-34. 5. Zhang J, Qiu LX, Wang ZH, Wang JL, He SS, Hu XC. NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 2010;123:877–83. 6. Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012;64:1388–98. 7. Canbaz D, Utsch L, Logiantara A, van Ree R, van Rijt LS. IL-33 promotes the induction of immunoglobulin production after inhalation of house dust mite extract in mice. Allergy 2015;70:522–32. 8.Ma XF, Wang XD, Liu RR, Luan QX.Efficacy research of salazosulfamide in ankylosing spondylitis and NAT1 gene polymorphism. Exp Ther Med. 2017 ;14(4):2999-3003. 9.Bartolomé N, Szczypiorska M, Sánchez A, Sanz J, Juanola-Roura X, Gratacós J, et al. Genetic polymorphisms inside and outside the MHC improve prediction of AS radiographic severity in addition to clinical variables. Rheumatology 2012; 51(8): 1471-8. 10.Ward MM, Weisman MH, Davis JC, Reveille JD. Risk factors for functional limitations in patients with long‐standing ankylosing spondylitis. Arthritis Care & Research 2005; 53(5): 710-7. 11.Haroon N, Kim T-H, Inman RD. NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Annals of the rheumatic diseases 2012; 71(10): 1593-5. 12.Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64(2): 235-48. 13.Frisch SM, Ruoslahti E. Integrins and anoikis. Current opinion in cell biology 1997; 9(5):701-6. 14.Schwartz MA. Integrins, oncogenes, and anchorage independence. The Journal of cell biology 1997; 139(3): 575-8. 15.Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285(5430): 1028-33. 16.Tamura M, Gu J, Tran H, Yamada KM. PTEN gene and integrin signaling in cancer. Journal of the National Cancer Institute 1999;91(21): 1820-8. 17.Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. Journal of Biological Chemistry 1998; 273(22): 13375-8. 18.Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer cell 2011; 19(6): 792-804. 19.Li D-M, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β. Cancer research 1997; 57(11): 2124-9. 20.Kong D, Suzuki A, Zou T-T, Sakurada A, Kemp LW, Wakatsuki S, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nature genetics 1997; 17(2): 143-4. 21.Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten+/− mice. Science 1999; 285(5436): 2122-5. 22.Wright C, Edelmann M, Kollnberger S, Kramer H, McGowan S, McHugh K, et al. Ankylosing spondylitis monocytes show upregulation of proteins involved in inflammation and the ubiquitin proteasome pathway. Annals of the rheumatic diseases 2009; 68(10): 1626-32. 23.Liu X, Karnell JL, Yin B, Zhang R, Zhang J, Li P, et al. Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. The Journal of clinical investigation 2010; 120(7): 2497-507. 24.Blüml S, Friedrich M, Lohmeyer T, Sahin E, Saferding V, Brunner J, et al. Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells. Annals of the rheumatic diseases 2013: Ann Rheum Dis 2015; 74(1): 227-33. 25.Baker SJ. PTEN enters the nuclear age. Cell 2007;128(1):25-8. 26.Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell 2007; 130(1): 25-35.